Roxithromycin

For the clinical treatment of common bacterial infectious diseases such as lower respiratory tract infections and skin and soft tissue infections, macrolide antibiotics have long been one of the mainstream medication options, and roxithromycin is a typical representative of the second-generation semi-synthetic varieties among them. It exerts antibacterial activity by reversibly binding to the 50S subunit of bacterial ribosomes and inhibiting bacterial protein synthesis, and has a strong inhibitory effect on pathogens including Gram-positive bacteria, anaerobes, mycoplasma and chlamydia. It is widely used in clinical treatment of infectious diseases such as pharyngitis, tonsillitis, sinusitis, pneumonia and urethritis in adults and children. Compared with erythromycin, it has higher oral bioavailability, longer half-life and lower incidence of gastrointestinal adverse reactions, thus presenting higher clinical compliance.

The current global market size of roxithromycin API exceeds USD 400 million, and the compound annual growth rate from 2023 to 2028 is expected to remain at around 3.2%. China is the world's largest producer and exporter of roxithromycin API, with its production capacity accounting for more than 75% of the global total capacity, and core manufacturers are concentrated in North China and East China. As the core patents have long expired, the continuous advancement of domestic generic drug consistency evaluation has been driving the growth of demand for upstream APIs. Coupled with the improved accessibility of antibacterial drugs in the primary medical market, the demand of downstream preparation enterprises for compliant APIs and supporting impurity research is increasing year by year.

CATO can provide a full set of impurity reference standards for roxithromycin API. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and all core impurities are available in stock, which can directly help API enterprises meet the full-process needs of quality research, registration declaration and daily quality control, shorten the R&D cycle and reduce compliance risks.